https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2019-05-30 09:00:412022-05-30 10:25:30Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2019-04-11 09:00:442022-05-30 10:24:32Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2019-01-18 09:00:012022-05-30 11:01:31Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2017-12-18 09:00:492022-08-17 15:15:29Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2017-07-10 09:00:392022-08-17 15:15:41Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2017-05-18 09:00:142022-08-17 15:15:52Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2017-03-15 09:00:262022-08-17 15:15:58Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2017-01-10 09:00:212022-08-17 15:16:05Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2016-08-09 09:00:182022-08-17 15:16:19Autifony Announces Results from Completed CLARITY-1, Phase IIa Trial of AUT00063 in Age-related Hearing Loss
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2016-08-01 09:00:002022-08-17 15:16:25Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia